Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).
Fayette J, Wirth L, Oprean C, Udrea A, Jimeno A, Rischin D, Nutting C, Harari PM, Csoszi T, Cernea D, O'Brien P, Hanley WD, Kapp AV, Anderson M, Penuel E, McCall B, Pirzkall A, Vermorken JB.
Fayette J, et al.
Front Oncol. 2016 Oct 31;6:232. doi: 10.3389/fonc.2016.00232. eCollection 2016.
Front Oncol. 2016.
PMID: 27843803
Free PMC article.